1. Signaling Pathways
  2. Epigenetics
    JAK/STAT Signaling
    Stem Cell/Wnt
  3. JAK
  4. JAK Inhibitors

JAK Inhibitors

JAK1

JAK2

JAK3

Tyk2

JAK

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.

JAK Inhibitors & Activators
Product Name JAK1 JAK2 JAK3 Tyk2 JAK Purity
Ruxolitinib
JAK1, IC50: 3.3 nM
JAK2, IC50: 2.8 nM
JAK3, IC50: 428 nM
Tyk2, IC50: 19 nM
  99.99%
Tofacitinib
JAK1, IC50: 112 nM
JAK2, IC50: 20 nM
JAK3, IC50: 1 nM
    99.96%
Baricitinib
JAK1, IC50: 5.9 nM
JAK2, IC50: 5.7 nM
JAK3, IC50: 560 nM
Tyk2, IC50: 53 nM
  ≥95.0%
BMS-986165
JAK1 JH2, IC50: 1 nM
   
Tyk2 JH2, IC50: 0.2 nM
  99.79%
BD750    
JAK3
    99.79%
JAK2/FLT3-IN-1
JAK1, IC50: 26 nM
JAK2, IC50: 0.7 nM
JAK3, IC50: 39 nM
   
JAK2-IN-7
JAK1, IC50: 42 nM
JAK2, IC50: 3 nM
JAK3, IC50: 94 nM
Tyk2, IC50: 75 nM
  99.42%
Upadacitinib
JAK1, IC50: 0.043 μM
JAK2, IC50: 0.2 μM
JAK3, IC50: 2.3 μM
Tyk2, IC50: 4.7 μM
  99.96%
Fedratinib  
JAK2, IC50: 3 nM
JAK2(V617F), IC50: 3 nM
      ≥98.0%
Ruxolitinib phosphate
JAK1, IC50: 3.3 nM
JAK2, IC50: 2.8 nM
JAK3, IC50: 428 nM
Tyk2, IC50: 19 nM
  ≥98.0%
Tofacitinib citrate
JAK1, IC50: 112 nM
JAK2, IC50: 20 nM
JAK3, IC50: 1 nM
    99.98%
Filgotinib
JAK1, IC50: 10 nM
JAK2, IC50: 28 nM
JAK3, IC50: 810 nM
Tyk2, IC50: 116 nM
  99.83%
Peficitinib
JAK1, IC50: 3.9 nM
JAK2, IC50: 5 nM
JAK3, IC50: 0.7 nM
Tyk2, IC50: 4.8 nM
  99.78%
WP1066  
JAK2
      99.90%
Pacritinib
JAK1, IC50: 1280 nM
JAK2V617F, IC50: 19 nM
JAK2wt, IC50: 23 nM
JAK3, IC50: 520 nM
Tyk2, IC50: 50 nM
  99.93%
Ritlecitinib    
JAK3, IC50: 33.1 nM
    99.98%
Itacitinib
JAK1
        99.97%
Momelotinib
JAK1, IC50: 11 nM
JAK2, IC50: 18 nM
JAK3, IC50: 155 nM
    98.93%
Delgocitinib
JAK1, IC50: 2.8 nM
JAK2, IC50: 2.6 nM
JAK3, IC50: 13 nM
Tyk2, IC50: 58 nM
  99.76%
Abrocitinib
JAK1, IC50: 29 nM
JAK2, IC50: 803 nM
 
Tyk2, IC50: 1253 nM
  99.79%
AZD-1480
JAK1, IC50: 1.3 nM
JAK2, IC50: <0.4 nM
      99.37%
Zotiraciclib  
JAK2, IC50: 73 nM
      99.96%
AT9283  
JAK2, IC50: 1.2 nM
JAK3, IC50: 1.1 nM
    99.61%
Gandotinib  
JAK2, IC50: 3 nM
JAK3, IC50: 48 nM
Tyk2, IC50: 44 nM
  99.96%
PF-06700841 P-Tosylate
JAK1, IC50: 17 nM
JAK2, IC50: 77 nM
JAK3, IC50: 6.9 μM
    99.66%
Lestaurtinib  
JAK2, IC50: 0.9 nM
      ≥99.0%
CHZ868  
JAK2, IC50: 110 nM
      99.22%
Oclacitinib maleate
JAK1, IC50: 10 nM
JAK2, IC50: 18 nM
JAK3, IC50: 99 nM
Tyk2, IC50: 84 nM
  99.65%
Cerdulatinib
JAK1, IC50: 12 nM
JAK2, IC50: 6 nM
JAK3, IC50: 8 nM
Tyk2, IC50: 0.5 nM
  99.0%
JANEX-1    
JAK3, IC50: 78 μM
    99.60%
Pyridone 6
Murine JAK1, IC50: 15 nM
JAK2, IC50: 1 nM
JAK3, IC50: 5 nM
Tyk2, IC50: 1 nM
  98.04%
BMS-911543
JAK1, IC50: 75 nM
JAK2, IC50: 1.1 nM
JAK3, IC50: 360 nM
Tyk2, IC50: 66 nM
  97.80%
Cucurbitacin I  
JAK2
      ≥98.0%
CEP-33779  
JAK2, IC50: 1.8 nM
JAK3, IC50: 150 nM
    99.36%
Baricitinib phosphate
JAK1, IC50: 5.9 nM
JAK2, IC50: 5.7 nM
JAK3, IC50: 560 nM
Tyk2, IC50: 53 nM
  99.91%
TG101209  
JAK2, IC50: 6 nM
JAK3, IC50: 169 nM
    99.72%
Ilginatinib
JAK1, IC50: 33 nM
JAK2, IC50: 0.72 nM
JAK3, IC50: 39 nM
Tyk2, IC50: 22 nM
  99.15%
Fedratinib hydrochloride hydrate  
JAK2, IC50: 3 nM
JAK2(V617F), IC50: 3 nM
      99.82%
SAR-20347
JAK1, IC50: 23 nM
JAK2, IC50: 26 nM
JAK3, IC50: 41 nM
Tyk2, IC50: 0.6 nM
  98.04%
Solcitinib
JAK1, IC50: 9.8 nM
        99.59%
XL019  
JAK2, IC50: 2.2 nM
JAK3, IC50: 214.2 nM
    ≥98.0%
NVP-BSK805 dihydrochloride
JAK1 JH1, IC50: 31.63 nM
JAK2 JH1, IC50: 0.48 nM
FL JAK2 V617F, IC50: 0.56 nM
FL JAK2 wt, IC50: 0.58 nM
JAK3 JH1, IC50: 18.68 nM
TYK2 JH1, IC50: 10.76 nM
  ≥98.0%
TyK2-IN-2      
Tyk2 JH2, IC50: 7 nM
  ≥98.0%
AZ960  
JAK2, Ki: 0.45 nM
JAK2, IC50: <3 nM
JAK3, IC50: 9 nM
    ≥98.0%
JAK/HDAC-IN-1
JAK1, IC50: 4.8 nM
JAK2, IC50: 4 nM
JAK3, IC50: 7.4 nM
Tyk2, IC50: 49 nM
  98.04%
Decernotinib
JAK1, Ki: 11 nM
JAK2, Ki: 13 nM
JAK3, Ki: 2.5 nM
Tyk2, Ki: 11 nM
  99.45%
Tyk2-IN-5      
Tyk2 JH2, Ki: 0.086 nM
  99.78%
AZD4205
JAK1, IC50: 73 nM
        ≥98.0%
ZM39923 hydrochloride
JAK1, pIC50: 4.4
 
JAK3, pIC50: 7.1
    99.86%
WHI-P154    
JAK3, IC50: 1.8 μM
    99.20%
Itacitinib adipate
JAK1
        ≥98.0%
Ruxolitinib (S enantiomer)        
JAK
99.92%
NSC 42834  
JAK2-WT, IC50: 15 μM
JAK2-V617F, IC50: 28 μM
      96.79%
FM-381    
JAK3, IC50: 127 pM
    98.25%
JAK3-IN-1
JAK1, IC50: 896 nM
JAK2, IC50: 1050 nM
JAK3, IC50: 4.8 nM
    99.98%
PF-06263276
JAK1, IC50: 2.2 nM
JAK2, IC50: 23.1 nM
JAK3, IC50: 59.9 nM
Tyk2, IC50: 29.7 nM
  ≥99.0%
Ilginatinib hydrochloride
JAK1, IC50: 33 nM
JAK2, IC50: 0.72 nM
JAK3, IC50: 39 nM
Tyk2, IC50: 22 nM
  98.02%
RO8191
JAK1
        ≥99.0%
SC99  
JAK2
      99.07%
SHR0302
JAK1
JAK2
JAK3
Tyk2
  99.58%
Reticuline  
JAK2
      98.11%
GLPG0634 analog    
JAK3, IC50: <100 nM
Tyk2, IC50: <100 nM
  98.58%
Momelotinib sulfate
JAK1, IC50: 11 nM
JAK2, IC50: 18 nM
JAK3, IC50: 155 nM
    ≥95.0%
Tyk2-IN-9
JAK1, IC50: 21 nM
JAK2, IC50: 8 nM
 
Tyk2, IC50: 6 nM
  99.62%
WHI-P97    
JAK3, IC50: 11 μM
    ≥98.0%
Ilginatinib maleate
JAK1, IC50: 33 nM
JAK2, IC50: 0.72 nM
JAK3, IC50: 39 nM
Tyk2, IC50: 22 nM
  97.04%
Cerdulatinib hydrochloride
JAK1, IC50: 12 nM
JAK2, IC50: 6 nM
JAK3, IC50: 8 nM
Tyk2, IC50: 0.5 nM
  99.54%
PF-06700841
JAK1, IC50: 17 nM
JAK2, IC50: 77 nM
JAK3, IC50: 6.9 μM
   
JAK3-IN-6    
JAK3, IC50: 0.15 nM
    98.07%
Protosappanin A  
JAK2
      98.88%
TCS 21311
JAK1, IC50: 1.017 μM
JAK2, IC50: 2.55 μM
JAK3, IC50: 8 nM
    ≥98.0%
JAK1-IN-4
JAK1, IC50: 85 nM
JAK2, IC50: 12.8 μM
     
JAK1-IN-7
JAK1
       
Tyk2-IN-7      
Tyk2 JH2, IC50: 0.00053 μM
Tyk2 JH2, Ki app: 0.00007 μM
 
JAK-IN-4        
JAK
JAK-IN-3
JAK1, IC50: 5 nM
JAK2, IC50: 70 nM
JAK3, IC50: 3 nM
Tyk2, IC50: 34 nM
 
BMS-986202      
Tyk2 JH2, IC50: 0.19 nM
Tyk2 JH2, Ki: 0.02 nM
 
JAK3 covalent inhibitor-1    
JAK3, IC50: 11 nM
   
Tyk2-IN-3      
Tyk2, IC50: 485 nM
 
JAK-2/3-IN-1  
JAK2, Ki: <250 nM
JAK3, Ki: <250 nM
   
BMS-066      
Tyk2, IC50: 72 nM
 
JAK2-IN-6  
JAK2, IC50: 22.86 μg/mL
     
ZM 449829
JAK1, pIC50: 4.7
 
JAK3, pIC50: 6.8
   
G5-7  
JAK2
      99.84%
2,6-Dichloro-N-(2-(cyclopropanecarboxamido)pyridin-4-yl)benzamide
JAK1, Ki: 0.7 nM
JAK2, Ki: 0.7 nM
JAK3, Ki: 0.4 nM
Tyk2, Ki: 4.8 nM
 
NSC 33994  
JAK2, IC50: 60 nM (JAK2 Val617Phe kinase activity )
     
FM-479    
JAK3
   
HG-7-85-01
JAK1, IC50: 120 nM
       
TCJL37      
Tyk2, Ki: 1.6 nM
 
Momelotinib Mesylate
JAK1, IC50: 11 nM
JAK2, IC50: 18 nM
JAK3, IC50: 155 nM
   
ZM39923
JAK1, pIC50: 4.4
 
JAK3, pIC50: 7.1